R01AI175232

Defining the Role of Immunoglobulin G4 (IgG4) in Food-Induced Eosinophilic Esophagitis (EOE) - Project Summary/Abstract

Over the past two decades, eosinophilic esophagitis (EOE) has transformed from a case-reportable disease to a major cause of upper gastrointestinal morbidity. EOE is primarily triggered by food, as diets eliminating common food allergens can lead to long-term disease remission. However, accurate tests to identify food triggers in individual patients do not yet exist because we do not fully understand the mechanisms of this food-induced inflammation.

We now know that this inflammation is not mediated by IgE, and diets based on IgE to foods have had limited success. In contrast, another immunoglobulin — IgG4 — is produced locally in the esophagus of EOE patients, and tissue levels of IgG4 correlate with disease activity. Using immunofluorescence (IF), we have generated preliminary data that IgG4 and food proteins co-localize in the esophageal tissue of EOE patients with active disease, which is suggestive of immune complex formation. We have further found that these IgG4-food deposits are located in close proximity to proteins associated with eosinophil activation, antigen presentation, and T cells.

Defining a role for IgG4 in the pathogenesis of EOE could fundamentally change our understanding of this condition — and of IgG4 — and could facilitate the development of novel diagnostic tests and therapies for this disease. Our overall hypothesis is that IgG4 contributes to food-induced inflammation in EOE.

In Aim 1, we will determine whether IgG4 forms immune complexes with food, which then promote high-avidity interactions to activate eosinophils in the esophageal tissue of patients with food-induced EOE.

In Aim 2, we will establish whether dendritic cell activation by IgG4-bound antigen amplifies the underlying T cell immune response in EOE. This will be assessed using 1) a validated milk challenge study where esophageal biopsies will be collected from EOE patients in remission on diet and after milk reintroduction and 2) in vitro stimulation assays using novel milk-specific IgG4 monoclonal antibodies (mAbs) generated from patients with EOE.

Our group is uniquely positioned to address this critical knowledge gap because of our access to large EOE populations, our expertise in novel spatial and T cell phenotyping techniques, and our ability to generate IgG4 mAbs for in vitro assays. We expect to find that IgG4 contributes to food-induced inflammation in EOE.

Regardless of the outcomes, these results will provide novel insights into the mechanisms of food-induced inflammation in EOE and may fundamentally change our understanding of the pathogenesis of this disease.

Rector & Visitors Of The University Of Virginia

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS; TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT; TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT; AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS; TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS; TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT; AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Charlottesville, Virginia 229044195 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 305% from $772,504 to $3,126,612.